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Abstract
Backbround: COPD is a common, highly debilitating disease of the airways, primarily caused by smoking. Chronic
inflammation and structural remodelling are key pathological features of this disease caused, in part, by the
aberrant function of airway smooth muscle (ASM). We have previously demonstrated that hydrogen sulfide (H2S)
can inhibit ASM cell proliferation and CXCL8 release, from cells isolated from non-smokers.
Methods: We examined the effect of H2S upon ASM cells from COPD patients. ASM cells were isolated from non-
smokers, smokers and patients with COPD (n = 9). Proliferation and cytokine release (IL-6 and CXCL8) of ASM was
induced by FCS, and measured by bromodeoxyuridine incorporation and ELISA, respectively.
Results: Exposure of ASM to H2S donors inhibited FCS-induced proliferation and cytokine release, but was less
effective upon COPD ASM cells compared to the non-smokers and smokers. The mRNA and protein expression of
the enzymes responsible for endogenous H2S production (cystathionine-β-synthase [CBS] and 3-mercaptopyruvate
sulphur transferase [MPST]) were inhibited by H2S donors. Finally, we report that exogenous H2S inhibited FCS-
stimulated phosphorylation of ERK–1/2 and p38 mitogen activated protein kinases (MAPKs), in the non-smoker
and smoker ASM cells, with little effect in COPD cells.
Conclusions: H2S production provides a novel mechanism for the repression of ASM proliferation and cytokine
release. The ability of COPD ASM cells to respond to H2S is attenuated in COPD ASM cells despite the presence of
the enzymes responsible for H2S production.
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Background
Hydrogen sulfide (H2S) which was discovered in human
tissues over 15 years ago, has emerged as an important
gaseous mediator in several biological processes [1]. H2S
is now considered the third member of a family of gaso-
transmitters, together with nitric oxide (NO) and carbon
monoxide [2]. The bulk of endogenous H2S synthesis in
mammalian tissues appears to be from the pyridoxal-5`-
phosphate–dependent enzymes, cystathionine-γ-lyase
(CSE) and cystathionine-β-synthase (CBS), and also by
3-mercaptopyruvate sulphur transferase (MPST) [3].
Chronic obstructive pulmonary disease (COPD) is a
common, highly debilitating disease of the airways, pri-
marily caused by smoking [4]. Serum H2S levels are sig-
nificantly increased in patients with stable COPD as
compared to age matched control subjects or those with
acute exacerbation of COPD [5]. Serum H2S levels were
negatively correlated with the severity of airway obstruc-
tion in patients with stable COPD whereas they were
positively correlated with the lung function in all pa-
tients with COPD and healthy controls. Patients with
acute exacerbations and increased pulmonary artery
pressure (PASP) had lower levels of H2S than those with
normal PASP, suggesting a negative relation between
H2S and PASP in COPD exacerbations. Serum H2S
levels are also lower in smokers than non-smokers
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regardless of their health status (COPD or healthy con-
trols). Furthermore, patients with acute exacerbations,
whose serum H2S levels were decreased, demonstrated
greater neutrophil numbers but lower lymphocyte num-
bers in sputum than patients with stable COPD, suggest-
ing a potential role of H2S in regulating inflammatory
response at different types or stages of COPD.
We have previously demonstrated that mitogen stimu-
lation increases inflammatory mediator release from
both ASM IL-6 and CXCL8 release in COPD patients to
a greater degree than those from non-smoker subjects
[4]. Furthermore, we have shown that H2S donors in-
hibit mitogen-induced inflammatory mediator release
and proliferation of cells from healthy non-smoking sub-
jects [6]. We therefore set out to determine the effect of
H2S in ASM cells isolated from healthy smokers and pa-
tients with COPD. We hypothesized that H2S may also
mediate ASM proliferation, and cytokine release to vary-
ing degrees in these diseased cells. We examined the ef-
fect of both exogenous and intracellular sources of H2S
in human ASM from 9 donors in each group upon pro-
liferation induced by fetal calf serum (FCS). We used
two extracellular H2S donors; the rapidly releasing H2S
donor, sodium hydrogen sulfide (NaSH), and modelled
endogenous H2S synthesis with the slow H2S-releasing
molecule, GYY4137 [6, 7]. To examine the role of en-
dogenously synthesized H2S, we used an inhibitor of
H2S synthesis (O-(carboxymethyl)-hydroxylamine hemi-
hydrochloride (CHH)) to inhibit CBS [6]. Finally, we also
investigated the role of mitogen-activated protein kinase
(MAPK) activation in this process.
Methods
Primary human ASM cell culture
Primary human ASM cells were previously dissected
from the lungs of healthy non-smokers, healthy smokers
and patients with COPD; disease and smoking status
were defined according to guidelines produced by the
American Thoracic Society [8]. Healthy smokers had a
smoking history of at least 10 pack years. There were
significant differences between FEV1 in litres, FEV1 per-
cent predicted, and FEV1/FVC ratio between smokers
and patients with COPD compared with non-smokers
but matched for age and smoking history (Table 1).
ASM cells were cultured and plated as previously de-
scribed [4, 6, 9–13]. ASM cells were plated onto 96-well
plates for the measurement of cytokine release, and six
well plates for RNA and protein extraction. Confluent
cells were growth-arrested by FCS deprivation for 24 h
in Dulbecco’s Modified Eagle’s Medium supplemented
with sodium pyruvate (1 mM), L-glutamine (2 mM),
nonessential amino acids (1:100), penicillin (100 U/ml)/
streptomycin (100 mg/ml), amphotericin B (1.5 mg/ml),
and BSA (0.1%) [6]. Cell at passages 3–4 from nine dif-
ferent donors per group were used.
Cells were stimulated in triplicate ±2.5% FCS for 1 h
before treatment with an H2S donor (NaSH or GYY4137
[100 μM]). 24 h later CBS, CSE and MPST mRNA and
protein expression was measured. At 8 days, cellular
proliferation was measured by BrdU assay (Roche Ap-
plied Science, West Sussex, UK), cellular viability by
MTT assay [14], and IL-6 and CXCL8 levels were deter-
mined by DuoSet ELISA (R&D Systems, Abingdon, UK)
as previously described [6]. For the inhibitor studies,
cells were treated with 1 mM O-(carboxymethyl)-hy-
droxylamine hemihydrochoride (CHH), 5 μM PD098059
(a MEK-1/2 inhibitor) or 5 μM SB 203580 (a p38 MAP
kinase inhibitor) for 30 min before treatment with NaSH
(100 μM) for a further 8 days.
RNA isolation and detection of mRNA expression
mRNA was isolated and CBS, CSE and 3-MST mRNA
expression levels were measured as previously described
[4, 6, 9–11].
Western blotting
Proteins were measured as previously described [4, 6, 9]
using mouse anti-CBS (A-2) antibody, a mouse anti-CSE
(30.7) antibody, mouse anti-MPST (H-11), rabbit anti-
p38 MAPK antibody and rabbit anti–phospho–p38
MAPK (Thr180/Tyr182) antibody (all from Santa Cruz
Biotechnology, Middlesex, UK) and, rabbit anti–extra-
cellular signal–regulated kinase (ERK)–1/2 (137F5)
and rabbit anti–phospho–ERK-1/2 (Thr202/Tyr204;
purchased from Cell Signalling Technology, Ely,
Cambridgeshire, UK).
Immunohistochemistry analysis of CSE, CBS and MPST in
bronchial biopsies
Cryostat sections from historical biopsies were stained
and scored as previously described [15]. Briefly, after
blocking non-specific binding sites with horse serum, 1:
Table 1 Characteristics of subjects providing airway smooth
muscle cells for culture
Non-smokers Smokers COPD
n 9 9 9
Age (y) 66.4 ± 12.72 59.2 ± 7.6 65.4 ± 6.6
Sex (♂ - ♀) 7–2 4–5 5–5
Pack years smoking N/A 29.25 ± 3.3 38.32 ± 2.92
FEV1 (L) 4.02 ± 0.48 3.12 ± 0.78 1.76 ± 0.45
FEV1 (% predicted) 104.23 ± 7.28 101.5 ± 4.51 77 ± 21.97
FEV1:FVC (%) 78.89 ± 5.98 77.57 ± 3.32 38.88 ± 15.75
Definition of abbreviations: FEV1 forced expiratory volume, FVC forced
vital capacity
Data shown as mean ± SEM
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200 primary antibody was applied in TRIS-buffered saline
(0.15 M saline containing 0.05 M TRIS-hydrochloric acid
at pH 7.6) and incubated for 1 h at room temperature in a
humid chamber. Antibody binding was demonstrated with
a secondary horse anti-mouse (Vector, BA 2000) antibody
followed by ABC kit HRP Elite, PK6100, Vectastain and
diaminobenzidine (DAB) substrate (brown colour).
Human tonsil or nasal polyp were used as positive con-
trols. For the negative control, normal mouse, rabbit or
goat non-specific immunoglobulins (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) were used at the same pro-
tein concentration as the primary antibody.
Data analysis
Data were analysed using GraphPad Prism, version 5.03
(GraphPad Software, San Diego, CA). Data were not
normally distributed (as assessed by the Kolmogorov-
Smirnov test), and therefore groups were compared
using the Dunn nonparametric test. All data are
expressed as means ± SEMs. Significance was defined
as a P value of less than 0.05.
Results
The presence of H2S producing enzymes in ASM cells
in-situ was determined by immunohistochemical stain-
ing of bronchial biopsies from healthy non-smokers,
healthy smokers and subjects with COPD. The most in-
tense staining was seen for CSE but no difference in the
expression of CSE, CBS or MPST was observed between
patient groups (Additional file 1: Figure S1).
Effect of H2S on FCS-induced ASM proliferation and
inflammatory mediator release
After 8 days of culture in the absence of FCS, neither
NaSH (100 μM) nor GYY4137 (100 μM) had any signifi-
cant effect upon cell viability in cells from any subject
group (Fig. 1a). ASM proliferation increased in the pres-
ence of 2.5% FCS (p < 0.001), an effect that was inhibited
by both NaSH and GYY4137 (p < 0.05) in all ASM
groups. However, there was a significant increase in the
level of proliferation between the patient groups, with
the highest level seen in the COPD patients compared
to non-smokers (p < 0.01). Furthermore, although the
H2S donors returned proliferation levels to baseline in
the non-smoker ASM cells, this was not the case in the
smokers or COPD patients (Fig. 1b). Similar results were
observed with regards to FCS-induced IL-6 (Fig. 1c), and
CXCL8 release (Fig. 1d) with both being greatest in
ASM from COPD subjects and having a lesser response
to NaSH and GYY.
Effect of H2S on CSE, CBS and MPST mRNA expression in
non-smokers, smokers and COPD patients
We next examined the effect of exogenous H2S upon
basal and FCS-exposed CSE, CBS and MPST mRNA ex-
pression. CSE mRNA expression did not alter under any
of the experimental parameters studied in any of the pa-
tient cohorts (Fig. 2a). NaSH (100 μM) alone had no ef-
fect on CBS mRNA levels at 24 h in any of the patient
groups. FCS (2.5%) enhanced CBS mRNA expression
only in the smokers (p < 0.05) and this was reversed back
Fig. 1 Effect of the hydrogen sulfide (H2S) donors, sodium hydrogen sulfide (NaSH) and GYY4137, on airway smooth muscle (ASM) from
non-smokers, smokers and COPD patients. ASM cells were incubated with FCS (2.5%) for 1 h; NaSH (100 μM) or GYY4137 (100 μM) was added for
another 8 days. Cellular growth and survival (a), DNA synthesis (b), IL-6 release (c), and CXCL8 release (d) were subsequently measured by
dimethylthiazol-diphenyltetrazolium bromide (MTT) assay, bromodeoxyuridine (BrdU) ELISA, and DuoSet ELISA respectively. Bars represent means
(± SEM) of nine ASM donors. */+/#P < 0.05; **/++/##P < 0.01; ***/+++/###P < 0.001
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to baseline by treatment with NaSH (100 μM). In
addition, NaSH also suppressed FCS-treated CBS mRNA
levels in ASMs from non-smokers (p < 0.05) (Fig. 2b).
FCS (2.5%) treatment for 24 h significantly up-
regulated the expression of MPST mRNA in ASMs from
non-smokers and smokers with significantly higher
levels in the smokers (p < 0.05) compared with non-
smokers (Fig. 2c). There was no effect of FCS on MPST
mRNA expression in cells from COPD patients. NaSH
(100 μM) alone had no effect on MPST mRNA expression
but reduced FCS-stimulated expression back to baseline
in cells from non-smokers and smokers (p < 0.05). No ef-
fect of NaSH was observed on FCS-treated COPD ASM
cells (Fig. 2c).
Effect of H2S on CSE, CBS and MPST protein expression in
non-smokers, smokers and COPD patients
Neither FCS nor NaSH had any effect on CSE protein
expression in ASM cells from any group studied (data
not shown). NaSH (100 μM) treatment alone had no
effect on CSE or MPST expression at 24 h (Fig. 3).
FCS (2.5%) increased CBS protein in the non-smokers
(p < 0.05) and smoker ASM cells (p < 0.01) but no
effect on CBS expression in COPD ASM cells. The
effect of FCS on CBS expression was significantly greater
in cells from smokers than non-smokers (p < 0.05).
NaSH (100 μM) suppressed FCS-induced CBS protein
production at 24 h in cells from smokers and non-
smokers (p < 0.01, p < 0.05 respectively) without affect-
ing expression in COPD cells (Fig. 3a & b).
Similarly, FCS (2.5%) enhanced MPST protein expres-
sion in ASMs from non-smokers (p < 0.05) and smokers
(p < 0.001). Treatment with NaSH (100 μM) completely
attenuated the ability of FCS to induce MPST pro-
tein at 24 h in cells from smokers and non-smokers
(p < 0.01, p < 0.05 respectively) (Fig. 3a & c). Again,
no effect on MPST protein expression was observed
in COPD ASM cells.
Effect of inhibiting CBS on ASM proliferation induced by
FCS in samples isolated from non-smokers, smokers and
COPD patients
ASM cells were pre-treated with an inhibitor of CBS
(CHH) for 30 min before treatment with 2.5% FCS with
or without NaSH (100μM) for 8 days. In ASMs from
non-smokers, CHH (1μM) significantly enhanced FCS-
stimulated proliferation (p < 0.01) to levels seen with FCS
alone in ASM cells from the COPD patients (Fig. 4a). A
similar ability of CHH to stimulate FCS-induced prolifera-
tion to levels seen in COPD cells was observed with ASM
cells from the smokers (p < 0.05). In contrast, CHH had
no effect on FCS-induced proliferation in ASMs from
patients with COPD (Fig. 4a). The ability of NaSH to sup-
press FCS-induced proliferation of ASMs from non-
smoker and healthy smoker cells was attenuated by the
presence of CHH (p < 0.01, p < 0.05 respectively) (Fig. 4a).
In contrast, the reduced ability of NaSH to suppress FCS-
stimulated proliferation in COPD ASM cells was not af-
fected by CHH.
A similar profile to that observed for proliferation
was seen in relation to FCS-stimulated IL-6 and CXCL8
Fig. 2 Effect of the H2S donor NaSH on CBS, CSE and MPST mRNA in human ASM cells from non-smokers, smokers and COPD patients.
ASM cells were incubated with FCS (2.5%) for 1 h and NaSH (100 μM) was added for another 24 h. Change in CBS (a), CSE (b), and MPST
(c) mRNA expression was subsequently measured by TaqMan RT-PCR. Bars represent means (± SEM) of nine ASM donors. */+/#P < 0.05;
**/++/##P < 0.01; ***/+++/###P < 0.001
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release (Fig. 4b & c). CHH enhanced FCS-induced IL-6
(Fig. 4b) and CXCL8 (Fig. 4c) release from cells from
non-smokers (p < 0.01) and smokers (p < 0.05) to levels
with COPD cells. In contrast, CHH had no effect on
FCS-induced proliferation in ASMs from patients with
COPD (Fig. 4b & c). The ability of NaSH to suppress
FCS-induced IL-6 (Fig. 4b) and CXCL8 (Fig. 4c) release
from ASMs from non-smoker and healthy smoker cells
was attenuated by the presence of CHH (p < 0.01). In
contrast, the reduced ability of NaSH to suppress FCS-
stimulated IL-6 (Fig. 4b) and CXCL8 (Fig. 4c) from
COPD ASM cells was not affected by CHH.
Fig. 4 Effect of inhibiting cystathionine-β-synthase (CBS) on ASM from non-smokers, smokers and COPD patients. ASM cells were incubated with
1 mM of an inhibitor of CBS (O-(carboxymethyl)-hydroxylamine hemihydrochloride [CHH]) for 30 min; media with 2.5% FCS was added for a
further 8 days with NaSH (100 μM). DNA synthesis (a), IL-6 release (b), and CXCL8 release (c) were subsequently measured by bromodeoxyuridine
(BrdU) ELISA and DuoSet ELISA respectively. Bars represent means (± SEM) of nine ASM donors. */+/#P < 0.05; **/++/##P < 0.01; ***/+++/###P < 0.001
Fig. 3 Effect of the H2S donor, NaSH on CBS and MPST protein expression in human ASM cells from non-smokers, smokers and COPD patients.
ASM cells were incubated with FCS (2.5%) for 1 h and NaSH (100 μM) was added for another 24 h. CBS, MPST and β-actin were detected by
Western blotting (a). Further examples are shown in Additional file 2: Figure S2. Changes in protein expression were quantified by densitometry,
normalized against β-actin expression, and then expressed as the percent change versus untreated controls (b & c). Bars represent means (± SEM)
of nine ASM donors. */+/#P < 0.05; **/++/##P < 0.01; ***/+++/###P < 0.001
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Effect of NaSH on activation of ERK-1/2 and p38 MAPK
We have previously reported that 2.5% FCS significantly
phosphorylates both ERK-1/2 and p38 MAPK in ASM
cells from non-smokers and that this is prevented by
NaSH [6]. We confirmed that FCS stimulates ERK-1/2
activation in non-smokers and demonstrate a similar in-
crease in cells from smokers but a greater activation
from COPD cells (Fig. 5a & b). Phosphorylation of ERK-
1/2 was significantly reduced by NaSH only in cells from
non-smokers (p < 0.05) (Fig. 5a & b). FCS induced a
greater level of p38 MAPK phosphorylation in cells from
smokers and COPD patients compared to that seen in
non-smokers (Fig. 5a & c). This phosphorylation was at-
tenuated by NaSH in cells from non-smokers and smokers
but not in cells from COPD patients (Fig. 5a & c).
Finally, we examined the role of the MAPKs, ERK-1/2
and p38, on FCS-induced proliferation (Fig. 6a), IL-6
(Fig. 6b) and CXCL8 (Fig. 6c) release in human ASM
cells. The ERK-1/2 inhibitor, PD98059 (5 mM), sig-
nificantly inhibited FCS-induced proliferation, IL-6
and CXCL8 release (p < 0.05) in all patient groups
(Fig. 6a, b & c). However, the magnitude of the effect
in COPD cells was less than that observed in smoker
and non-smoker cells. The p38 MAPK inhibitor,
SB202190 (5 mM), had a reduced effect compared to
that seen with PD98059. The combination of
PD98059 and SB202190 had a greater suppressive ef-
fect on all parameters than the individual inhibitors
across all subject groups but again the magnitude of
the effect in COPD cells was less.
Furthermore, when the ASM cells were further treated
with NaSH (100μM) in addition to the MAPK inhibitors,
a further decrease in IL-6 and CXCL8 release was ob-
served in the COPD patients (P < 0.05) although this still
failed to reach baseline levels as seen in cells from
smokers and non-smokers (Fig. 6b & c).
Discussion
For the first time, we demonstrate that both endogenous
and exogenous H2S inhibits human ASM cell prolifera-
tion and cytokine release induced by FCS, and that this
effect was dependent on the patient. Specifically; prolif-
eration and cytokine release from non-smoker ASM
cells returned to basal levels (as previously reported [6])
whereas in smokers, both IL-6 and CXCL8 release were
reduced to baseline but proliferation although being sig-
nificantly reduced did not return to basal levels. In con-
trast, the effect of H2S on proliferation and cytokine
release from ASM cells isolated from COPD patients
was impaired compared to smokers and non-smoker
Fig. 5 Effect of the H2S donor, NaSH on FCS-induced activation of extracellular signal–regulated kinase (ERK)–1/2 and p38 mitogen-activated
protein kinase (MAPK) in human ASM cells from non-smokers, smokers and COPD patients. ASM cells were incubated with FCS (2.5%) for 1 h and
NaSH (100 μM) was added for another 24 h. Total and phospho–ERK-1/2, total and phospho-p38 and β-actin were detected by Western blotting
(a), and the corresponding densitometry graphs are shown in b & c. Further examples are shown in Additional file 2: Figure S2. Changes in
phospho-MAPK expression were quantitated by densitometry, normalized against β-actin expression, and then expressed as the percent change
versus non phosphorylated controls. Bars represent means (± SEM) of nine ASM donors. */+/#P < 0.05; **/++/##P < 0.01; ***/+++/###P < 0.001. **P < 0.01.
P-ERK, phosphorylated- ERK; P-p38, phosphorylated p38
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cells. Furthermore, we have shown that endogenous H2S
is produced by the enzymes CBS and MPST, and not by
CSE. We found that H2S differentially inhibited phos-
phorylation of the MAPKs, ERK-1/2 and p38, according
to the patient group and propose that this could be a
mechanism by which H2S inhibits cellular proliferation
and cytokine release [4, 16–19].
ASM proliferation is increased in response to FCS
[9, 10, 20] and studies have examined the role of H2S
upon cell proliferation. These have concluded that
this gas can induce proliferation [21] or, conversely,
inhibit it [6, 22, 23] depending upon the cell type exam-
ined. Both the fast-release H2S donor, NaSH, and the
slow-release donor, GYY4137, have been used previously
to affect inflammation in both in-vivo and in-vitro models
of inflammation, including a mouse models of vascular in-
flammation and oxidative stress [24], asthma [25], COPD
[26], and a rat model of colitis [27]. Our data extends our
previous report demonstrating the inhibitory action of
H2S in non-smoker ASM cells [6] and examined its role
in smoker and COPD ASM cells. Both NaSH and
GYY4137 caused similar inhibitory effects on FCS-
Fig. 6 Effect of mitogen-activated protein kinase 1/2 (MEK-1/2) and p38 MAPK inhibition upon FCS-induced proliferation, IL-6 and CXCL8 release
in human ASM cells from non-smokers, smokers and COPD patients. ASM cells were incubated with an MEK-1/2 (5 mM) inhibitor, a p38 (5 mM)
inhibitor, or both for 30 min. The ASM cells were then further incubated with NaSH (100 μM) for another 8 days. DNA synthesis (a), IL-6 release
(b), and CXCL8 release (c) were subsequently measured by bromodeoxyuridine (BrdU) ELISA, and DuoSet ELISA respectively. Bars represent means
(± SEM) of nine ASM donors. *P < 0.05 versus cells plus 2.5% FCS; **P < 0.01 versus cells plus 2.5% FCS; ***P < 0.001 versus cells plus 2.5% FCS;
#P < 0.05 versus cells plus 2.5% FCS plus NaSH; ##P < 0.01 versus cells plus 2.5% FCS plus NaSH
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induced ASM cell proliferation, IL-6 and CXCL8 release
from smokers as well as non-smokers indicating that the
rate of release does not modulate the inhibitory effect of
H2S in ASM. We also show for the first time, an effect
upon primary ASM cells isolated from patients with
COPD. However, the effect of H2S donors is reduced
compared to that seen in cells from smokers and non-
smokers which may explain, in part, the increased
inflammatory and proliferative status of COPD cells.
Indeed, the H2S enzyme inhibitor CHH had no signifi-
cant effect on FCS-induced inflammatory protein
release from COPD cells in contrast to the effect seen
in cells from other subject groups.
We found that, all three H2S producing enzymes are
expressed in ASM cells to a similar extent across the
subject groups studied. However, our pharmacological
studies suggest that endogenous H2S production is these
cells is most likely to be through the enzymes, CBS, and
MPST. In cultured ASM cells, FCS was able to induce
CBS and MPST mRNA and protein in cells from non-
smokers and smokers but not in COPD cells suggesting
that mitogens may induce cells to produce more H2S.
NaSH inhibited both CBS and MPST, likely as a
negative-feedback inhibitory mechanism. Currently, CBS
appears to be involved in the generation of endogenous
H2S in neural pathways, the brain, vascular tissue, and
non-smoker ASM cells [6, 28–32]. In contrast, CSE is
predominantly involved in endogenous H2S production
in rodent smooth muscle and the lung [33–37], and
MPST maintains mitochondrial function [extensively
reviewed in [38, 39]]. Clearly cell, species and pathology
differences should be taken into consideration when in-
vestigating the production of endogenous H2S.
A role for the ERK-1/2 and p38 MAPKs in regulating
ASM cell proliferation and cytokine release is well docu-
mented [4, 16–19] and H2S has been shown to affect the
phosphorylation of these kinases [6, 26, 40–43]. Hence,
we examined the degree of phosphorylation of these
kinases in our COPD ASM cells. We noted that FCS in-
duced both ERK-1/2 and p38 MAPK phosphorylation,
which was reduced by NaSH in both the non-smoker and
smoker ASM cells, but no effect was seen in the COPD
cells. Inhibiting these kinases significantly reduced the
ASM proliferation and cytokine release and, when they
were used before treatment with NaSH, a further decrease
in aberrant phenotype was observed, further supporting
the possibility that the mechanism of H2S, at least in part,
is via the inhibition of these kinases.
Finally, our data shows that ASM cells of COPD patients
indicate an attenuated response to H2S, as compared to the
non-smoker and smoker-groups. But the question remains,
why? There are numerous reviews discussing both the im-
portance of H2S in chronic respiratory diseases [3, 44] and
smooth muscle itself [45], however recent studies
demonstrate further actions of this gasotransmitter. For ex-
ample, Fitzgerald et al. demonstrate that H2S causes the
relaxation of human ASM and implicate the role for sarco-
lemmal KATP channels [46]. In mouse models, Huand et
al. indicate that H2S can induce mouse ASM relaxation by
activating BKCa [47], and Castro-Piedras et al. indicate that
H2S causes ASM relaxation by inhibiting Ca
(2+) release
through InsP3Rs and consequent reduction of agonist-
induced Ca(2+) oscillations [48]. In other rodent models of
lung pathology, endogenous H2S has been suggested to
have a protective role of anti-inflammation and broncho-
dilation in chronic cigarette smoke-induced pulmonary in-
jury in rats [49], and H2S provokes tachykinin-mediated
neurogenic inflammation that is mediated by stimulation of
TRPV1 receptors on the sensory nerve endings in Guinea
Pigs [50]. Furthermore, considering the emergence of data
suggesting a degree of cross-talk between H2S and epi-
genetic modifiers such as miRNAs [51, 52], and our
own data suggesting broadly different epigenetic pro-
files between lung pathologies (including COPD) in
ASM [4, 9, 10, 12, 13]. Hence, the difference between a
COPD ASM cell and a ‘healthy’ASM cell may incorporate
one, or more likely, more of these H2S targets/activators.
To address this further we intend to further these and
other findings in our murine model of COPD [26].
Conclusion
In conclusion, we have shown for the first time that H2S
inhibits both human ASM proliferation and cytokine re-
lease induced by FCS, differentially between ASM cells
isolated from non-smokers, smokers and patients with
COPD. It is likely that exogenous H2S targets the pro-
duction of endogenous H2S by inhibiting the transcrip-
tion and subsequent translation of the CBS and MPST
enzymes, and proliferation is controlled by H2S through
a negative-feedback pathway. H2S inhibits the activity of
the ERK-1/2 and p38 MAPKs, in the non-smokers and
smokers, but with little effect in the COPD ASM cells.
We propose that H2S may provide a novel therapeutic
avenue in the stabilization of ASM proliferation but that
its effectiveness in COPD may be more limited.
Additional files
Additional file 1: Figure S1. Immunohistochemistry staining of CSE,
CBS and MPST in bronchial biopsies from non-smokers, smokers and
COPD patients. Photomicrographs showing representative photomicro-
graphs of cystathionine-γ-lysase (CSE), cystathionine-β-synthase (CBS) and
3-mercaptopyruvate sulphur transferase (MPST) staining in the bronchial
mucosa from control non-smokers, control smokers with normal lung
function and mild/moderate COPD patients. Immune-stained airway
smooth muscle cells are indicated by brown staining. Results are
representative of those from 13 non-smokers, 14 smokers with normal
lung function, 15 mild/moderate COPD patients. Calibration bar
represents 20 μm. Graphical representation of the results are shown in
the right hand panels. (JPG 332 kb)
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Additional file 2: Figure S2. Further examples of the effect of the H2S
donor, NaSH on CBS and MPST protein expression, and activation of
extracellular signal–regulated kinase (ERK)–1/2 and p38 mitogen-activated
protein kinase (MAPK) in human ASM cells from non-smokers, smokers
and COPD patients. ASM cells were incubated with FCS (2.5%) for 1 h
and NaSH (100 μM) was added for another 24 h. CBS, MPST (A), Total and
phospho–ERK-1/2, total and phospho-p38 and β-actin (B) were detected
by Western blotting. (JPG 212 kb)
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